{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T19:02:14Z","timestamp":1770750134465,"version":"3.50.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008304"],"award-info":[{"award-number":["2020YFC2008304"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Science and Technology Project of Henan Province","award":["LHGJ20220425"],"award-info":[{"award-number":["LHGJ20220425"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Idiopathic inflammatory myopathies (IIM) are a heterogeneous and life-threatening group of diseases; in particular, anti-melanoma differentiation-associated gene 5 antibody positive DM (MDA5+ DM) is reportedly strongly associated with high mortality rate. Tacrolimus (TAC) provides an excellent therapeutic option, but the trough concentration (Cmin)\u2013outcome relationship remains unexplored. This study was undertaken to identify optimal Cmin and individualized dose based on CYP3A5 genotype for IIM patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 134 IIM patients with 467 Cmin were enrolled. We examined the relationship between TAC Cmin and relapses. The receiver operating characteristic analysis was used to confirm the optimal Cmin. Analyses of factors influencing Cmin were conducted. The dose requirement based on CYP3A5 genotype was confirmed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TAC Cmin is strongly associated with relapses. The optimal cutoff values were 5.30, 5.85, 4.85 and 5.35\u2009ng\/ml for acute, subacute, chronic and all-phase IIM patients (P\u2009=\u20090.001, 0.013, 0.002 and &amp;lt;0.001, respectively), as well as 5.35, 5.85, 5.55 and 5.85\u2009ng\/ml for acute, subacute, chronic and all-phase MDA5+ DM patients (P\u2009=\u20090.007, 0.001, 0.036 and &amp;lt;0.001, respectively). CYP3A5 genotype was one of the significant factors influencing TAC Cmin. CYP3A5 expressers required 0.059\u2009mg\/kg\/day to attain the target Cmin, while nonexpressers required 0.046\u2009mg\/kg\/day (P\u2009=\u20090.019).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TAC treatment may elicit favorable outcome in patients with IIM and MDA5+ DM when Cmin exceeded 5.35 and 5.85\u2009ng\/ml, which is crucial to a lower relapse rate. The individualized dose based on the CYP3A5 genotype provides a reference for TAC personalized therapy in IIM.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae316","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T18:27:53Z","timestamp":1718735273000},"page":"2569-2577","source":"Crossref","is-referenced-by-count":1,"title":["Tacrolimus personalized therapy based on <i>CYP3A5<\/i> genotype in Chinese patients with idiopathic inflammatory myopathies"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-1708","authenticated-orcid":false,"given":"Xueke","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China"},{"name":"Henan Key Laboratory of Precision Clinical Pharmacy , Zhengzhou, China"},{"name":"Henan Engineering Research Center for Application & Translation of Precision Clinical Pharmacy , Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-6578","authenticated-orcid":false,"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University , Zhengzhou, China"},{"name":"Henan Key Laboratory of Precision Clinical Pharmacy , Zhengzhou, China"},{"name":"Henan Engineering Research Center for Application & Translation of Precision Clinical Pharmacy , Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"2024090404221369700_keae316-B1","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/art.41762","article-title":"Expert perspective: management of refractory inflammatory myopathy","volume":"73","author":"Lundberg","year":"2021","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2024090404221369700_keae316-B2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024090404221369700_keae316-B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41584-022-00879-0","article-title":"Mapping the immune landscape of MDA5(+) dermatomyositis","volume":"19","author":"McHugh","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2024090404221369700_keae316-B4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/medicina57040347","article-title":"Management of myositis-associated interstitial lung disease","volume":"57","author":"Fujisawa","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2024090404221369700_keae316-B5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12890-015-0154-4","article-title":"Interstitial lung disease in clinically amyopathic dermatomyositis with and without anti-MDA-5 antibody: to lump or split?","volume":"15","author":"Ikeda","year":"2015","journal-title":"BMC Pulm Med"},{"key":"2024090404221369700_keae316-B6","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/art.42264","article-title":"Two distinct immune cell signatures predict the clinical outcomes in patients with amyopathic dermatomyositis with interstitial lung disease","volume":"74","author":"Ye","year":"2022","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2024090404221369700_keae316-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2018.1521185","article-title":"Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists","volume":"29","author":"Kohsaka","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2024090404221369700_keae316-B8","doi-asserted-by":"crossref","first-page":"978429","DOI":"10.3389\/fimmu.2022.978429","article-title":"The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: a retrospective and prospective study","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"2024090404221369700_keae316-B9","first-page":"939","article-title":"Chinese Expert consensus on the diagnosis and treatment of adult dermatomyositis (2022)","volume":"55","author":"Jin","year":"2022","journal-title":"Chin J Dermatol"},{"key":"2024090404221369700_keae316-B10","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology (Oxford, England)"},{"key":"2024090404221369700_keae316-B11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"2024090404221369700_keae316-B12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"2024090404221369700_keae316-B13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/1756-185X.13414","article-title":"Efficacy and safety of oral high-trough level tacrolimus in acute\/subacute interstitial pneumonia with dermatomyositis","volume":"22","author":"Suzuka","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"2024090404221369700_keae316-B14","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.semarthrit.2020.03.007","article-title":"Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease","volume":"50","author":"Romero-Bueno","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2024090404221369700_keae316-B15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clinical pharmacology and therapeutics"},{"key":"2024090404221369700_keae316-B16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monitor"},{"key":"2024090404221369700_keae316-B17","first-page":"532","article-title":"Monitoring of peripheral blood cluster of differentiation 4+ adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseases","volume":"15","author":"Muraki","year":"2018","journal-title":"Exp Ther Med"},{"key":"2024090404221369700_keae316-B18","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024090404221369700_keae316-B19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/annrheumdis-2019-215488","article-title":"First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)\/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort","volume":"79","author":"Jinnin","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024090404221369700_keae316-B20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2024090404221369700_keae316-B21","first-page":"1409","article-title":"Expert consensus on individual treatment of tacrolimusin solid organ transplantation","volume":"21","author":"Wenqian","year":"2021","journal-title":"Eval Anal Drug-Use Hosp China"},{"key":"2024090404221369700_keae316-B22","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis and rheumatism"},{"key":"2024090404221369700_keae316-B23","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024090404221369700_keae316-B24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.42308","article-title":"Identification of three different phenotypes in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis patients: implications for prediction of rapidly progressive interstitial lung disease","volume":"75","author":"Xu","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2024090404221369700_keae316-B25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjd.14882","article-title":"Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis","volume":"176","author":"Matsushita","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024090404221369700_keae316-B26","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology (Oxford, England)"},{"key":"2024090404221369700_keae316-B27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/EJA.0000000000001166","article-title":"Noninvasive respiratory support in the hypoxaemic peri-operative\/periprocedural patient: a joint ESA\/ESICM guideline","volume":"37","author":"Leone","year":"2020","journal-title":"Eur J Anaesthesiol"},{"key":"2024090404221369700_keae316-B28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"2024090404221369700_keae316-B29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/gtmb.2020.0077","article-title":"Tacrolimus starting dose prediction based on genetic polymorphisms and clinical factors in chinese renal transplant recipients","volume":"24","author":"Wang","year":"2020","journal-title":"Genet Test Mol Biomarkers"},{"key":"2024090404221369700_keae316-B30","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3899\/jrheum.161217","article-title":"Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort","volume":"44","author":"Sharma","year":"2017","journal-title":"J Rheumatol"},{"key":"2024090404221369700_keae316-B31","doi-asserted-by":"crossref","first-page":"e98824","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PLoS ONE"},{"key":"2024090404221369700_keae316-B32","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","article-title":"The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2024090404221369700_keae316-B33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejim.2023.01.018","article-title":"The efficacy and safety of tacrolimus in patients with dermatomyositis\/polymyositis: a meta-analysis and systematic review","volume":"110","author":"Liao","year":"2023","journal-title":"Eur J Intern Med"},{"key":"2024090404221369700_keae316-B34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024090404221369700_keae316-B35","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2024090404221369700_keae316-B36","doi-asserted-by":"crossref","first-page":"813117","DOI":"10.3389\/fmed.2022.813117","article-title":"A prediction model for tacrolimus daily dose in kidney transplant recipients with machine learning and deep learning techniques","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Med"},{"key":"2024090404221369700_keae316-B37","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/tri.12194","article-title":"Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation","volume":"26","author":"\u00c5sberg","year":"2013","journal-title":"Transpl Int"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae316\/58303323\/keae316.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2569\/59007450\/keae316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/9\/2569\/59007450\/keae316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T11:24:34Z","timestamp":1725449074000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/9\/2569\/7695895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,6,18]]},"published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae316","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,6,18]]}}}